Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes-Radioactive & Nonradioactive - Radiopharmacy & Clinical Production

Cu-Mediated 18F-Fluorination of Arylboronic Acids: Supressing Protodeboronation towards Advanced PET Imaging Agents

Carolin Jaworski, Jingkai Sun, Dennis Hall and Ralf Schirrmacher
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242485;
Carolin Jaworski
1University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingkai Sun
1University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dennis Hall
1University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf Schirrmacher
1University of Alberta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

242485

Introduction: Cu-mediated radiofluorinations (CMRFs) of arylboronic acids and esters are readily available. Unfortunately, the generation of undesired protodeboronation byporducts and their implications in radiotracer separation negatively affects in vivo binding of radiotracers due to competitive target binding. Therefore, surppressing or avoiding protodeboronation in CMRFs would improve radiotracer quality, patient care and PET imaging outcomes.

Methods: As a starting point, non-radioactive (19F) Cu-mediated nucleophilic fluorinations of 4-biphenylboronic acid as model compound were performed to find the optimal reaction conditions to enhance fluorination while suppressing protodeboronation. Parameters such as solvent, copper source, additives, composition of fluoride labeling cocktail and the reaction temperature were evaluated. The optimized reaction conditions for the 19F-fluorination of 4-biphenylboronic acid using KBF4 (fluoride source), Cu(ONf)2 (copper salt), 18-crown-6 (additive), t-BuOH (solvent) in a 30 minute reaction at 60 °C were used to further establish a radiofluorination protocol for various boronic acids. Radiochemical conversions (RCCs) were determined using radio thin-layer chromatography (ratio-TLC). Radio high-performance liquid chromatography (radio-HPLC) was used to quantify the amount of protodeboronation occurring during these novel reaction conditions and comparing the amount to established methods in the field.

Results: Optimal radiofluorination conditions were established. Fluorine-18 (18F) was trapped using a 130 mg carbonate QMA and eluted using a solution containing K2CO3 and 18‑crown‑6 in MeCN and water (v/v, 8:1) followed by azeotropic drying and re-suspending in anhydrous t-BuOH. Adding this 18F-stock solution to the boronic acid or ester precursor together with Cu(ONf)2 and stirring it for 30 minutes at 60 °C resulted in RCCs of 9-54% (Scheme 1) for a prototypical series of eight (hetero)aryl boronic acids and two (hetero)aryl pinacol-derived boronic esters. With a reliable radiofluorination method in hand, we investigated the amount of protodeboronation produced under these reaction conditions (Table 1, protocol A) using radio-HPLC and a mass calibration curve. Further, the influence on protodeboronation when doubling the amount of Cu(ONf)2 (Table 1, protocol B) as well as switching Cu(ONf)2 to Cu(OTf)2 (Table 1, protocol C) was investigated and lastly compared to an established method from the literature (protocol D). Our protocol A significantly decreased the amount of protodeboronation to 30 nmol in comparison to the literature value of 400-800 nmol (protocol D). Doubling the amount of Cu(ONf)2 (protocol B) did not significantly influence the amount of protodeboronation nor the RCC. Using Cu(OTf)2 instead of Cu(ONf)2 (protocol C) dropped the amount of protodeboronation to a minimum of 6 nmol but at the cost of a significant drop in RCC.

Conclusions: Our modified 18F-labeling protocol successfully suppressed protodeboronation to 30 nmol in comparison to 400-800 nmol stated in the literature while still maintaining good RCCs between 9-54%. Overall, these studies give insight on factors influencing protodeboronation in CMRFs and it is assumed that the suppressed protodeboronation will have a positive effect on PET imaging quality. Higher resolution in PET images will ultimately improve diagnosis and therefore earlier detection and better patient care.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Cu-Mediated 18F-Fluorination of Arylboronic Acids: Supressing Protodeboronation towards Advanced PET Imaging Agents
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Cu-Mediated 18F-Fluorination of Arylboronic Acids: Supressing Protodeboronation towards Advanced PET Imaging Agents
Carolin Jaworski, Jingkai Sun, Dennis Hall, Ralf Schirrmacher
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242485;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cu-Mediated 18F-Fluorination of Arylboronic Acids: Supressing Protodeboronation towards Advanced PET Imaging Agents
Carolin Jaworski, Jingkai Sun, Dennis Hall, Ralf Schirrmacher
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242485;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Assessment of the Radiochemical Purity and Chemical Identity of [225Ac]Ac-Labeled Radiotherapeutics by TLC and RP-HPLC
  • Roadmap for the accelerated development and clinical translation of fluorescent tracers using adalimumab-680LT
Show more Molecular Targeting Probes-Radioactive & Nonradioactive - Radiopharmacy & Clinical Production

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire